BAY-439: Potent Inhibitor of Human Phospholipase A2 Group V for Inflammatory Pain Research

2.4 KB of data describes the identification of the piperidyl urea derivative BAY-439 as a potent and selective inhibitor of human Phospholipase A2 Group V (hPLA2-G5). The dataset, authored by Gernot Langer and last updated on 2026-05-19, contains information on this chemical probe accepted by the Structural Genomics Consortium and its inactive negative control, BAY-163.

Use Cases

• Benchmarking inhibitor potency and selectivity based on the described single-digit nanomolar activity.
• Investigating the role of hPLA2-G5 in chronic inflammation models based on its described link to arachidonic acid and PGE2 production.
• Studying structure-activity relationships for hPLA2-G5 inhibitors based on the described optimization from high-throughput screening hits.
• Using BAY-439 and BAY 163 as pharmacological tools to probe hPLA2-G5 function in physiological and pathological conditions as described.

Strengths

• Data describes a chemical probe accepted by the Structural Genomics Consortium, suggesting community validation.
• Includes information on both an active inhibitor (BAY-439) and an inactive negative control (BAY-163) for controlled experiments.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (2.4 KB), indicating limited scope, likely containing summary or identifier information rather than extensive experimental data.

Provenance

Source

figshare, author Gernot Langer.

Collection Method

Likely contains results from high-throughput and fragment-based screening followed by compound optimization.

Time Range

null

Freshness

Last updated 2026-05-19 08:31:04; freshness should be verified.

Geography

null